InvestorsHub Logo
Followers 0
Posts 194
Boards Moderated 0
Alias Born 04/14/2024

Re: None

Sunday, 04/28/2024 8:44:46 PM

Sunday, April 28, 2024 8:44:46 PM

Post# of 43443
LENZI which was bought for nothing to hgenq shareholders. Now in business, if assets are so below 'fair value' it can be void and buyer knows it's below fair value. I don't know what law that voids transactions. but if an asset was sold to cheap and sold to insiders it considere 'embezzlement' which is why all gov't assets are sold in an OPEN public auction, and anyone with cash can bid on it. In this case of LENZI auction it was NOT an open bid auction. and people were not allowed to bid on it. so it was NOT sold at 'fair price' and seller didn't actively solicit bidders, and based on the conditions, it discouraged any bidder or didn't respond to interested bidders.
In most 'auction's the price of the asset is already known, before the auction is held. and bidders just participate and pay 'fair price'

These drug patents are worth a lot of money if it sells as insurance companies are paying for these treatments 3.5 million/treatment. Who would have that kind of money if they don't have the 3.5 million and no insurance?
these are rare diseases and only a few pay for them.

The treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told CNBC. It has a hefty $3.5 million price tag before insurance and other rebates, the spokesperson added, making it by far one of the most expensive drugs in the U.S.

https://www.cnbc.com/2024/04/26/fda-approves-pfizer-gene-therapy-beqvez-for-treatment-of-hemophilia-b.html
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.